Certain Medicare plans typically cover at least part of the cost of inhalers for COPD. There are also several ways to further save on costs.
“Patients with mild-to-moderate COPD who have low exercise tolerance are likely to experience poor respiratory health outcomes,” the investigators concluded. “Exercise tolerance may be considered one ...
Injurious falls are common among people with chronic obstructive pulmonary disease (COPD) in the two years before de ...
Inhalers for COPD provide steroids, bronchodilators, or combination drugs. The three types differ in the mechanism by which the medication is inhaled and have different instructions for use.
Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...
A recent study conducted by researchers from Seattle-based University of Washington and Durham, N.C.-based Duke University found a strong association between the use of fall-risk increasing drugs and ...
Asthma, chronic obstructive pulmonary disease (COPD) and lung cancer cause extensive mortality and morbidity worldwide. However, the current state-of-the-art diagnosis and management schemes of ...
Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.
Stimulant medications are considered the first-line treatment for ADHD for some very good reasons. Here are 6 things to know about stimulant medications in ADHD. Attention Deficit Hyperactivity ...
A new study suggests COPD patients experience improved lung ... as both can be fearful of losing control of the disease in a change of medication. The CRYSTAL trial is the first large-scale ...
The drug is likely to be the first COPD triple therapy on the market, after Europe’s CHMP committee recommended a marketing authorisation late last month. But while it waits for the European ...